肌层浸润性膀胱癌新辅助化疗后临床完全缓解的保守治疗:多中心当代结局
该多中心回顾性研究纳入2001至2017年148例肌层浸润性膀胱癌患者,均在接受经尿道膀胱肿瘤电切术和新辅助铂类化疗后达到临床完全缓解并选择主动监测。中位随访55个月,5年疾病特异性生存率90%、总生存率86%、无膀胱切除生存率76%、无复发生存率64%;48%出现膀胱复发,其中11%为肌层浸润。结论支持在严格筛选和密切监测的患者中主动监测的安全性。
要点
- 临床完全缓解定义为化疗后电切无肿瘤、细胞学阴性及横断面影像正常。
- 5年疾病特异性生存率90%、总生存率86%、无膀胱切除生存率76%。
- 48%膀胱复发,11%为肌层浸润;挽救性膀胱切除可防多数癌症死亡。
核心结论
- 对新辅助化疗后达到临床完全缓解的肌层浸润性膀胱癌患者,主动监测可获较高总生存率和疾病特异性生存率并保留膀胱。
- 结局支持在严格筛选和密切监测的患者中安全实施主动监测。
研究设计与样本
- 多中心回顾性队列研究,纳入2001至2017年两家机构中经尿道膀胱肿瘤电切术和新辅助铂类化疗后达临床完全缓解并选择监测的肌层浸润性膀胱癌患者148例。
- 中位随访55个月(范围5至145个月)。
主要发现
- 5年疾病特异性生存率90%、总生存率86%、无膀胱切除生存率76%、无复发生存率64%。
- 71例(48%)出现膀胱复发,其中16例(11%)为肌层浸润性疾病,55例(37%)为非浸润性疾病。
- 肌层浸润复发后行挽救性膀胱切除者12例中9例(75%)避免癌症特异性死亡,非浸润复发后行膀胱切除者14例中13例(93%)避免癌症特异性死亡。
关键数值与推荐
- 临床完全缓解定义为化疗后经尿道膀胱肿瘤电切术无肿瘤、细胞学阴性及横断面影像正常。
临床怎么用
- 对严格筛选、密切监测的肌层浸润性膀胱癌患者,在新辅助化疗后达临床完全缓解时可考虑主动监测以保留膀胱。
- 复发后行挽救性膀胱切除可有效预防癌症特异性死亡。
局限性
- 回顾性研究设计。
- 需未来研究识别预测浸润性复发的生物标志物和开发早期检测的新影像方法以改善患者选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We report the outcomes in patients with muscle invasive bladder cancer from 2 institutions who experienced a clinically complete response to neoadjuvant platinum based chemotherapy and elected active surveillance. It was unknown whether conservative treatment could be safely implemented in these patients. MATERIALS AND METHODS: We retrospectively reviewed the records of patients with muscle invasive bladder cancer at our institutions who elected surveillance following a clinically complete response to transurethral resection of bladder tumors and neoadjuvant chemotherapy from 2001 to 2017. A clinically complete response was defined as absent tumor on post-chemotherapy transurethral resection of bladder tumor, negative cytology and normal cross-sectional imaging. RESULTS: In the 148 patients followed a median of 55 months (range 5 to 145) the 5-year disease specific, overall, cystectomy-free and recurrence-free survival rates were 90%, 86%, 76% and 64%, respectively. Of the patients 71 (48%) experienced recurrence in the bladder, including 16 (11%) with muscle invasive disease and 55 (37%) with noninvasive disease. Salvage radical cystectomy prevented cancer specific death in 9 of 12 patients (75%) who underwent cystectomy after muscle invasive relapse and in 13 of 14 (93%) after noninvasive relapse. CONCLUSIONS: We observed high rates of overall and disease specific survival with bladder preservation in patients who achieved a clinically complete response to neoadjuvant chemotherapy. These outcomes support the safety of active surveillance in carefully selected, closely monitored patients with muscle invasive bladder cancer. Future studies should aim to improve patient selection by identifying biomarkers predicting invasive relapse and developing novel imaging methods of early detection.
引用
- Mazza P, Moran GW, Li G, et al. Conservative Management Following Complete Clinical Response to Neoadjuvant Chemotherapy of Muscle Invasive Bladder Cancer: Contemporary Outcomes of a Multi-Institutional Cohort Study. J Urol. 2018. PMID: 29787740. doi:10.1016/j.juro.2018.05.078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。